NMPA Approved IND Application of XNW5004

XNW5004, an EZH2 inhibitor with independent intellectual property rights owned by Evopoint.

As an epigenetic drug, it can regulate the expression of tumor suppressor genes to inhibit tumor growth. IND was approved by NMPA on April 14, 2021, and will initiate phase I clinical trial soon.